TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

Approval Granted for Phase II Clinical Trial in China of TT-01488 Tablets in Combination with Anti-CD20 Monoclonal Antibody for the Treatment of Mantle Cell Lymphoma

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") announces that the Phase II clinical trial of the Company's product, TT-01488 tablets, in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma (MCL), was approved by the National Medical Products Administration (NMPA) on 1 July 2026.

This trial is a multi-center, open-label, dose-finding, and dose-expansion Phase II study to evaluate TT-01488 tablets in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma.

TT-01488 is a novel, non-covalent BTK inhibitor developed by the Company. Kinase profiling shows that it possesses excellent target activity, low affinity for EGFR and Tec, and superior kinase selectivity. This can reduce off-target inhibition, decrease adverse effects such as atrial fibrillation and bleeding, and offer better safety potential. Furthermore, it has demonstrated favorable anti-tumor activity in tumor lymphocyte xenograft models. Multiple clinical studies have confirmed that the combination of BTK inhibitors and anti-CD20 monoclonal antibodies can improve the efficacy of first-line treatment for mantle cell lymphoma (MCL). In the completed Phase I clinical trial of TT-01488, among 10 efficacy-evaluable patients with non-blastoid MCL, the objective response rate (ORR) was 70%, including 4 complete responses and 3 partial responses. Its unique mechanism of action, paired with anti-CD20 monoclonal antibody, can synergize targeted killing and immune effects, holding promise for establishing a highly effective, low-toxicity, "chemo-free" first-line treatment option.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.

By Order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 1 July 2026

As at the date of this announcement, the Board comprises Dr. Frank Wu and Mr. Wu Di as executive Directors; Ms. Jia Zhongxin as a non-executive Director; and Mr. Li Shu Pai, Ms. Chui Hoi Yam and Mr. Feng Weibo as independent non-executive Directors.